SB-431542


SB-431542 is a drug candidate developed by GlaxoSmithKline as an inhibitor of the activin receptor-like kinase receptors, ALK5, ALK4 and ALK7. However, it is not an inhibitor of anaplastic lymphoma kinase.

In-vitro studies

While SB-431542 has not proved directly useful for any clinical application, it is used for several applications in molecular biology. It suppresses the TGF-beta-induced proliferation of osteosarcoma cells in humans. SB431542 can also be used in combination with LDN193189, CHIR99021 and DAPT to transform astrocytes into neurons. It is also commonly used for immunological studies, for instance as a TGF-β inhibitor to facilitate the generation of dendritic cells from peripheral blood monocytes.